Investment in state-of-the-art automation cements Abingdon Health’s position as a leading global rapid test manufacturer
Abingdon Health is pleased to announce further expansion at its headquarters in York, UK, following further investment in state-of-the-art lateral flow automation. This will provide a significant increase in its manufacturing footprint, resulting in one of Europe's largest capacity for rapid test manufacturing.
This news comes weeks after the UK Government announced Abingdon Health as one of the leading members of the UK Rapid Test Consortium (UK-RTC).
Earlier this year, Abingdon Health announced a preliminary round of expansion in York after 90 % revenue growth in 2019, thanks to new assay development and assay manufacturing contract wins, and the introduction of its AppDx® Smartphone reader software. In April 2020, growth continued with the acquisition of a new lateral flow manufacturing facility in Doncaster, UK. This latest expansion and investment in equipment, which has been captured in a new video, comes as 2020 sees continuing high demand for Abingdon Health’s services.
Abingdon Health’s two manufacturing sites in York and Doncaster have the capacity to produce millions of rapid tests per month for clients across many industries. This adaptable, dual-site approach forms a peace-of-mind solution that assures customers receive product consistency and a security of supply during routine scheduling and spikes in demand.
Chris Yates, CEO of Abingdon Health, commented:
“The additional footprint and automation come at a timely moment as demand for rapid tests is growing rapidly, with the market likely to exceed $10bn globally. Our precision automation and multi-site approach means we can adapt to meet the varying manufacturing needs of our growing global client base.”
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.